Full text is available at the source.
Abstract
The prevalence of obesity among patients with inflammatory bowel disease (IBD) is rising.
- Obesity in IBD patients is associated with worse disease outcomes.
- Diminished treatment response is observed in obese individuals with IBD.
- Glucagon-like peptide-1 receptor agonists (GLP-1RA) may be safe and effective for IBD patients with obesity.
- The study explores potential anti-inflammatory mechanisms of GLP-1RA in this context.
Simplified